<DOC>
	<DOCNO>NCT00907582</DOCNO>
	<brief_summary>For relapse acute promyelocytic leukemia all-trans retinoic acid ( ATRA ) arsenic treatment , remission achieve chemotherapy ATRA and/or arsenic addition mylotarg . Autologous hematopoietic cell transplantation use polymerase chain reaction ( PCR ) negative graft important treatment option obtain sustainable remission . This study test efficacy safety condition regimen idarubicin busulfan relapse Acute Promyelocytic Leukemia ( APL ) .</brief_summary>
	<brief_title>ASCT Relapsed APL After Molecular Remission</brief_title>
	<detailed_description>Once relapse acute promyelocytic leukemia achieve molecular remission all-trans retinoic acid ( ATRA ) arsenic treatment , PBSC mobilize collect confirmation molecular remission via RT-PCR . Patients receive autologous hematopoietic cell transplantation .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<criteria>Men woman age 1860 year old Acute promyelocytic leukemia relapse confirm cytogenetics ( 15 ; 17 ) molecular analysis ( PMLRARalpha ) Mobilized peripheral CD34+ 2x106/kg negative PMLRAR alpha confirm PCR European Cooperative Oncology Group performance status 03 Serum bilirubin &lt; 1.5x upper limit normal ( ULN ) Serum alanine transaminase ( ALT ) /aspartate transaminase value &lt; 2.5 x ULN Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Woman child bear potential Serum creatinine &gt; 400 Micromol/l initial resuscitation patient previous Grade 24 peripheral neuropathy Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug ) Uncontrolled severe cardiovascular disease include myocardial infarction within 6 month enrollment , uncontrolled angina , clinically significant pericardial disease , IIIIV heart failure Known allergy idarubicin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>PCR negative</keyword>
</DOC>